Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Looking ahead, ...

Accolade Inc (ACCD) surpasses revenue expectations and maintains a robust cash position, while navigating market pressures ...

Shares in Accolade Inc (NASDAQ:ACCD) jumped after the company reported a narrower-than-expected loss and strong margin growth for the fiscal Q2 2025.

Personalized healthcare company Accolade Inc (NASDAQ:ACCD) stock is trading slightly higher after the company announced ...

Accolade (ACCD) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Accolade Inc (NASDAQ:ACCD) is set to release its Q2 2025 earnings on Oct 8, 2024. The consensus estimate for Q2 2025 revenue ...

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. “As we enter the second half of fiscal year 2025, we ...

Ladies and gentlemen, thank you for standing by. Welcome to Accolade's second-quarter 2025 earnings results conference call. (Operator Instructions) Please be advised that today's conference is being ...

Accolade, Inc. (ACCD) on Tuesday reported a loss of $23.9 million in its fiscal second quarter. The Seattle-based company said it had a loss of 30 cents per share. The results beat Wall Street ...

Given the large stake in the stock by institutions, Accolade's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 10 shareholders Ownership research ...

The company’s overall score improved to 73, placing it in the 95th percentile of companies evaluated by EcoVadis.

Global philanthropic organization Yidan Prize Foundation has awarded the 2024 Yidan Prize, the world's highest education ...